Critics question study on stents, others doubt much impact

03/28/2007 | NYTimes.com · Wall Street Journal, The

Some critics of a trial showing drugs should be tried before angioplasty note only 3% of participants with stents received the latest drug-coated models. Still, there remain questions about whether the study will have much impact on the market for stents, which is already experiencing a sag in sales because of recent safety concerns.

View Full Article in:

NYTimes.com · Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC